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INTRODUCTION
Although epidemiologic and experimental evidences favor
a strong role of chemical carcinogens in the etiology of bladder
cancer, many cases arise without obvious exposure to known
carcinogens (1). It is likely that all malignancies involve aber-
rations of normal mechanisms regulating cell differentiation
and proliferation, often with derangements in the genetic com-
position of malignant cells. Since mechanisms usually exist
in all cells to repair mutated or miscopied DNA or to affect
the death of cells containing such altered DNA, the failure
of these safeguard mechanisms must occur in most, if not all,
malignancies. All of these influences undoubtedly play impor-
tant roles in determining the development of bladder cancer.
Apoptosis is clearly an advantageous response to DNA da-
mage if DNA repair fails, because it allows multicellular
organisms to eliminate potentially harmful cells. Eliminat-
ed cells can be replaced from the organism’s pool of undam-
aged cells. Depending on the location, environment, or extent
of damage, apoptosis may even be a primary response (2).
Therefore, it is not surprising that aberrations in apoptosis
can be detrimental and that the failure of dividing cells to
initiate apoptosis after sustaining severe DNA damage con-
tributes to cancer (3).
Survival factors suppress the intrinsic cell-death machin-
ery, thereby preventing apoptosis (4). Forkhead box O-class
(FOXO) transcription factors, including FOXO1, FOXO3a,
and FOXO4, function as tumor-suppressor proteins by in-
hibiting cell proliferation, promoting apoptosis, and protect-
ing cells from oxidative stress and DNA damage. The poten-
cy of these functions is tightly regulated by phosphorylation,
acetylation, and ubiquitination. FOXO1 is a key regulator of
glucose homeostasis, cell-cycle progression, and apoptosis
(5). Emerging evidence indicates that protein levels of FOXO1
are regulated by phosphoinositide-3-kinase-protein kinaseB
(PI3K-PKB/c-Akt)-mediated phosphorylation. Akt is high-
ly active in human cancers due to the loss of phosphatase and
tensin homolog (PTEN) (6). FOXO1 is modulated by fork-
head box G1 (FOXG1), another member of the Fox transcri-
ption factor family, which acts as a transcriptional repressor
with oncogenic potential (7). FOXG1 recognizes some of the
same targets as FOXO, but functions as a repressor rather
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Forkhead box O-class 1 and Forkhead box G1 as Prognostic Markers
for Bladder Cancer
Forkhead box O-class 1 (FOXO1) is a key regulator of glucose homeostasis, cell-
cycle progression, and apoptosis. Its functions are modulated by forkhead box G1
(FOXG1), which acts as a transcriptional repressor with oncogenic potential. Real-
time PCR and immunohistochemical staining were performed in 174 primary blad-
der cancer specimens and 21 normal bladder mucosae to evaluate these genes.
FOXO1 and FOXG1 mRNA expression in cancer tissues were higher than in nor-
mal mucosae (each P<0.001). FOXO1 mRNA levels were significantly higher in
samples of non-progressed patients (P<0.001), but FOXG1 were enhanced in those
of progressed patients (P=0.019). On univariate analysis, FOXO1 mRNA expres-
sion was significantly associated with grade, stage, recurrence, progression and
survival (each P<0.05). On multivariate analysis, increased FOXO1 mRNA expres-
sion was associated with both reduced disease progression (odds ratio [OR], 0.367;
95% confidence interval [CI], 0.163-0.826, P=0.015) and enhanced disease-free
survival (OR, 3.262; 95% CI, 1.361-7.820, P=0.008). At a median follow-up of 33
months (range 2 to 156), the patients with a high FOXO1 mRNA expression had a
significantly prolonged survival (P=0.001). Immunohistochemical findings of FOXO1
were generally concordant with mRNA expression levels. In conclusion, FOXO1
may be a promising marker for predicting progression in human bladder cancers.
Key Words : FOXO1; FOXG1; Urinary Bladder Neoplasms; Prognostic Factor; Real Time PCR; Immunohisto-
chemistry
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than an activator (8).
However, little is known about the properties and roles of
FOXO1 and FOXG1 in human bladder cancer. In this study,
we explored relationships between these genes and clinico-
pathologic characteristics in bladder cancer patients using
real-time polymerase chain reaction (PCR) and immunohis-
tochemical staining.
MATERIALS AND METHODS
Patients and tissue samples
One hundred and seventy-four primary bladder cancer sam-
ples were taken in the Chungbuk National University Hos-
pital, Cheongju, Korea. Histological diagnoses revealed that
all patients had transitional cell carcinoma. Table 1 lists demo-
graphic data. Twenty one normal bladder tissues were ob-
tained from patients with benign diseases. These were dis-
sected in order to separate from the mucosa from the under-
lying smooth muscle, which were histologically confirmed
normal mucosae on frozen sections. Informed consent was
obtained from each subject and the study was approved by
the Institutional Review Board of the Chungbuk National
University College of Medicine. Median follow-up was 33
months (range 2 to 156). In this study, we defined the super-
ficial recurrence as the cancer recurrence of primary superfi-
cial bladder cancer without progression, and the progression
as the cancer progression both of superficial bladder cancer
to invasive or metastatic disease and of invasive cancer to
metastatic disease after adequate treatment. All specimens
were rapidly frozen in liquid nitrogen and stored at -80℃
until the RNAs were extracted. 
Real-time PCR
Total RNA was isolated from the tissues with TRIzol rea-
gent (Life Technologies, NY, U.S.A.) according to the man-
ufacturer’s instructions. cDNA was prepared from 1 μ g of
total RNA by random priming using a First-Strand cDNA
Synthesis Kit (Amersham Biosciences Europe GmbH, Frei-
burg, Germany) according to the manufacturer’s protocol.
To quantify the expression levels of FOXO1, real-time PCR
amplification was performed with a Rotor Gene 3000 PCR
instrument (Corbett Research, Mortlake, Australia). Quan-
titative values were obtained from the cycle threshold (Ct)
number at which increase in the signal associated with expo-
nential growth of PCR products began to be detected. Glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) was cho-
sen as an endogenous RNA reference gene. Each sample was
checked on the basis of its GAPDH content. Real-time PCR
assays using SYBR Premix EX Taq (TAKARA BIO INC.,
*Determined using the t-test.
FOXO1, Forkhead box O-class 1; FOXG1, Forkhead box G1.
FOXO1
(×10
3 copies/μ L)
FOXG1
(×10
3 copies/μ L)
P* P* No. of patients (%) Variables
Sex
Male     145 (83.3)
Female    29 (16.7)
Age (yr) 64.58±0.89
Normal versus cancer
Normal 21 14.57±1.11 <0.001 0.92±0.1 <0.001
Cancer 174 71.17±1.11 2.58±0.4
Stage
Superficial 111  (63.8) 93.86±1.14 0.001 2.57±0.42 0.966
Invasive 63 (36.2) 43.71±1.18 2.60±0.61
Grade
Low 116  (66.7) 82.44±1.14 0.048 2.08±0.81 0.134
High 58 (33.3) 53.03±1.19 1.81±0.46
Superficial recurrence
No recurrence  72 (64.9) 113.92±1.18 0.042 2.53±0.55 0.173
Recurrence 39 (35.1) 65.64±1.23 3.49±0.85
Progression
No progression  135 (77.6) 87.38±1.13 <0.001 2.37±0.38 0.019
Progression 39  (22.4) 34.98±1.20 4.84±1.07
Survival
Alive 137  (78.7) 87.66±1.13 0.001 2.68±0.42 0.239
Dead 37  (21.3) 34.33±1.19 3.96±0.99
Table 1. Clinico-pathological features and mRNA expression levels of FOXO1 and FOXG1 in primary bladder transitional cell carcinomas470 T.-H. Kim, S.-W. Jo, Y.S. Lee, et al.
Otsu, Japan) were carried out in micro-reaction tubes (Cor-
bett Research). The PCR reaction was performed in a final
volume of 10 μ L, consisting of 5 μ L of 2×SYBR Premix EX
Taq buffer, 0.5 μ L of each 5′ - and 3′ -primer (10 pM/μ L), and
1 μ L of sample cDNA. To amplify the target and reference
genes, the primers were used to amplify: FOXO1 (153 bp)
5′ -atggtcaagagcgtgccc-3′ and 5′ -gattgagcatccaccaag-3′ ; and
FOXG1 (150 bp), 5′ -ttcagctacaacgcgctcat-3′ and 5′ -acaga-
ttgtggcggatggag-3′ . 
The product was purified with a QIAquick Gel Extrac-
tion Kit (QIAGEN, Hilden, Germany), quantified with a
spectrophotometer (Perkin Elmer MBA2000, Shelton, CT,
U.S.A.), and sequenced with an automated laser fluorescence
sequencer (ABI PRISM 3100 Genetic Analyzer, Shelton, CT,
U.S.A.). The known concentration of the product was 10-
fold serially diluted from 4.05×105 copies/μ L to 4.05×102
copies/μ L. The dilution series of the PCR products were used
to establish the standard curve for the real-time PCR. The
real-time PCR conditions were 1 cycle at 96℃ for 20 sec,
followed by 40 cycles of 2 sec at 96℃, 20 sec at 60℃, and
20 sec at 72℃. The melting program was performed at 72-
95℃ with a heating rate of 1℃ per 45 sec. Spectral data
were captured and analyzed using Rotor-Gene Real-Time
Analysis Software 6.0 Build 14 (Corbett Research, Mortlake,
Australia).
Immunohistochemical staining
Immunohistochemical staining was performed in matched
174 archival bladder tissue paraffin blocks. All cases were
retrospectively identified from the surgical pathology files of
the same hospital and the corresponding slides were reviewed
to reconfirm the pathological parameters including grade
and stage. All archival materials were routinely fixed in 10%
neutral-buffered formalin and embedded in paraffin. Sections
(4 μ m) were prepared on silane-coated slides (Sigma, St. Louis,
MO, U.S.A.). A DakoCytomation Immunostaining Kit (Glo-
strup, Denmark) was used. Tissue sections on microslides
were deparaffinized with xylene, hydrated in serially-dilut-
ed alcohol, and immersed in 3% H2O2 to quench endoge-
nous peroxidase activity. For antigen retrieval, the slides were
treated with microwaves in 10 mM borate buffer (pH 8.0)
for 15 min. The sections were then incubated with primary
antibodies (Santa Cruz Biotechnology, Inc. Santa Cruz, CA,
U.S.A.) for 60 min, rinsed three times with washing buffer,
and further incubated for 20 min with an Envision detection
system (anti-rabbit; DakoCytomation). After rinsing, immu-
nostaining was performed for 5 min with liquid 3,3′ -diami-
nobenzidine (DiNonA, Seoul, Korea). The sections were then
counterstained with Meyer’s hematoxylin, dehydrated, and
mounted with Canada balsam. The rinsing solution was dis-
tilled water with 0.1% TWEEN 20. Three independent in-
vestigators evaluated the immunohistochemical staining with-
out knowledge of the clinicopathologic parameters. FOXO1
staining was mainly cytoplasmic. As cognate anti-FOXG1
antibody was not commercially available, we were unable to
study this factor immunohistochemically. 
For semiquantitative assessment of the immunohistochem-
ical results, the mean percentage of positive tumor cells was
determined in at least 10 random fields at ×400 magnifica-
tion in each section. It was graded as focal (10%), regional
(11-50%), or diffuse (>50%). The intensity of immunoreac-
tion was graded weak, moderate, or intense. The mean per-
centage of positive tumor cells and the staining intensity were
then combined to produce immunohistochemical results.
The results were graded as negative (0), moderate regional
(1), moderate diffuse (2), intense regional (3), and intense dif-
fuse (4). Inter-observer differences were minimal. The consen-
sus opinions were used to assign final scores to the disputed
cases before data analysis.
Statistical analysis
All statistical analyses were carried out using the SPSS pack-
age, Release 10.0 (SPSS Inc., Chicago, IL, U.S.A.). Because
of its highly skewed distribution, the FOXO1 and FOXG1
mRNA data were examined as the natural log function and
subsequently back transformed for the interpretation of the
model results. The mRNA data were presented as the means
and SEMs. Student’s t-tests were applied to assess the asso-
ciation of the mRNA expression levels with the development,
progression, recurrence of the cancer and with survival. Pear-
son’s correlation was used for the relation between the expres-
sion level of FOXO1 and FOXG1. Multivariate logistic regres-
sion analyses were also performed to identify the factors that
had a significant effect on cancer progression and survival.
We used receiver-operating-characteristic (ROC) curves to
analyze FOXO1 mRNA levels in order to determine the cut-
off point (51.48×103 copies/μ L) that yielded the highest
combined sensitivity and specificity for disease-free survival.
Kaplan-Meier curves were generated and compared by the
log rank test for survival rates. The immunohistochemical
data were analyzed using chi-square method. 
RESULTS
Quantification of FOXO1 and FOXG1 mRNA expression
levels
Considerably higher FOXO1 and FOXG1 expression were
observed in bladder cancer tissues than in normal mucosae
(each P<0.001). Table 1 summarizes the expression levels of
FOXO1 and FOXG1 according to the stage, grade, superfi-
cial recurrence, progression, and disease-free survival of blad-
der cancer. The FOXO1 expression levels in superficial blad-
der cancers were significantly higher than in invasive cancers
(P<0.001). FOXO1 expression levels were significantly ele-Relationship Between Bladder Cancer and Expression of FOXO1 and FOXG1 471
vated in low-grade compared with high-grade bladder can-
cers (P=0.048). FOXG1 did not show any relations with the
stage and grade of bladder cancer (each P>0.05).
In the superficial bladder cancers, the expression levels of
FOXO1 were enhanced in non-recurred patients compared
with recurred patients (P=0.042), whereas FOXG1 did not.
The FOXO1 mRNA levels were significantly higher in blad-
der cancer tissues from the patients without progression than
in progressed cases (P<0.001). In contrast, the expression of
FOXG1 mRNA in primary bladder cancer that had progre-
ssed was enhanced compared to cases that had not (P=0.019).
In addition, a weak negative correlation between mRNA
expression levels of FOXO1 and FOXG1 was observed in
bladder cancer tissues (Pearson’s sample correlation coeffi-
cient r=-0.220, P=0.008).
The association between the FOXO1 expression levels and
the disease-free survival of patients was also analyzed. Our
data showed that the patients with elevated FOXO1 mRNA
expression in their primary bladder cancers had significant
survival benefits compared to those with low expression. Ex-
pression levels of FOXO1 in primary cancer tissues of living
patients were significantly higher than in those of deceased
cases (P<0.001).
Multivariate analysis results showed that the cancer stage
and FOXO1 mRNA expression level were strong predictors
of cancer progression and disease-free survival (Table 2). In
particular, increased FOXO1 mRNA expression levels were
associated with both reduced disease progression (odds ratio
[OR], 0.367; 95% confidence interval [CI], 0.163-0.826, P=
0.015) and enhanced disease-free survival (OR, 3.262; 95%
CI, 1.361-7.820, P=0.008).
Fig. 1 shows the Kaplan-Meier analyses of bladder can-
cer disease-free survival stratified by FOXO1 mRNA expre-
ssion level. The patients with elevated FOXO1 mRNA exp-
ression level in their primary bladder cancers had significant
survival benefit compared to those with low-expression (P=
0.001).
Expression of FOXO1 by immunohistochemical staining
Immunohistochemistry revealed cytoplasmic staining of
FOXO1 in urinary bladder cancers (Fig. 2). Table 3 shows the
relationship between expression levels of FOXO1 and blad-
der cancer. FOXO1 expression levels were significantly higher
in low-grade cancers than in high-grade cancers (P<0.001).
FOXO1 was more strongly expressed in superficial bladder
FOXO1, Forkhead box O-class 1; 95% CI, 95% confidence interval.
95% CI P Odds ratio Variables
Prediction of progression
Age 1.198 0.536-2.678 0.660
Sex 1.964 0.766-5.032 0.160
Grade 0.904 0.336-2.435 0.842
Stage 4.308 1.598-11.615 0.004
mRNA expression levels  0.367 0.163-0.826 0.015
of FOXO1
Prediction of disease-free survival
Age 0.326 0.271-1.543 0.326
Sex 0.613 0.223-1.685 0.343
Grade 1.496 0.523-4.280 0.452
Stage 0.111 0.037-0.329 <0.001
mRNA expression levels   3.262 1.361-7.820 0.008
of FOXO1
Table 2. Multivariate logistic regression analyses of age, sex,
grade, stage, and FOXO1 mRNA expression levels in bladder
cancers for the prediction of bladder cancer progression and
disease-free survival
Fig. 2. The FOXO1 expression shows strong cytoplasmic reactiv-
ity on urothelial cancer cells (×200).
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cancers than in invasive cancers (P<0.001). Although FOXO1
expression was higher in patients with recurrence than in
those without recurrence, the difference was not statistically
significant (P=0.143). FOXO1 expression in bladder cancer
tissues from non-progressed patients was significantly high-
er than in those from progressed cases (P=0.005). A signifi-
cant correlation was also found between FOXO1 expression
levels and disease-free survival (P=0.003).
DISCUSSION
The FOXO family is regulated by the PI3K-PKB/c-Akt
pathway. PKB-induced phosphorylation inhibits transcrip-
tional activity of the FOXO members, which control the cell
cycle, cell death, cell metabolism, and response to oxidative
stress (9). Studies in mammalian cells have shown that the
overproduction of FOXO1 induces either cell-cycle arrest or
apoptosis (9). By increasing the production of the cyclin-de-
pendent kinase inhibitor p27kip1, FOXO transcription fac-
tors cause cell-cycle arrest in the G1 phase of the cell cycle
(10). Recently, FOXO factors have also been implicated in
the control of proper progression through the G2-M phase
of the cell cycle (11). The production of FOXO family mem-
bers can also cause cell death by apoptosis (12).
Support for a connection between FOXO proteins and on-
cogenic transformation is provided by another Fox family pro-
tein, FOXG1. This transcription factor was originally iden-
tified as brain factor 1 and has also been recovered as the re-
troviral oncoprotein Qin in ASV31 (13, 14). The oncogenic
transformation induced by retroviral expression of FOXG1
directly correlates to transcriptional repression (7, 15). In ad-
dition, FOXG1 binds the consensus sequence tgtaaacaaa (15),
which is similar to the binding motif for FOXO proteins (gt-
aaacaa) (16). Using cotransfections of FOXO1 and FOXG1
with the reporter pGL3-CMV-3xIRS, Aoki et al. demonstra-
ted that FOXG1 is a strong inhibitor of FOXO1-mediated
transcriptional activation. They suggested that FOXG1 and
FOXO1 might negatively and positively regulate a shared su-
ite of target genes, respectively (17).
In this study, we investigated the mRNA expression levels
of FOXO1 and FOXG1 in human bladder cancer. This is the
first study to investigate the relationships between the expres-
sion of these genes and clinico-pathological parameters in blad-
der cancer to our knowledge. Our data shows that FOXO1
and FOXG1 are more highly expressed in bladder cancer tis-
sues than in normal bladder mucosae, which suggests that
FOXO1 might be activated during tumorigenesis in the blad-
der. At present, the exact mechanisms for enhanced expres-
sion of FOXO1 and FOXG1 in bladder cancer are unknown.
One possible explanation is based on the relationship between
FOXO1 and FOXG1. The function of FOXO1 is further mod-
ulated by FOXG1. FOXG1 acts as a transcriptional repressor,
has oncogenic potential (7), and can repress some of the same
targets that are activated by FOXO1 (8). Therefore, FOXO1
expression might increase to compete with FOXG1 suppres-
sion. Another possible explanation for enhanced FOXO1 ex-
pression may be that, a variety of much stronger oncogenic
activity mask the protective effect of FOXO1.
We also analyzed the expression levels of FOXO1 in relation
to the clinical findings in bladder cancer patients. FOXO1
immunohistochemical findings were generally in concordance
with mRNA expression levels, suggesting that FOXO1 ex-
pression might be primarily determined at the transcription-
*Test for a linear trend across the immunohistochemical staining score; 
� 0 for negative, 1 for moderate regional, 2 for moderate diffuse, 3 for intense
regional, 4 for intense diffuse.
FOXO1, Forkhead box O-class 1.
P*
Immunohistochemical staining score (%)
�
0123 4
Variables
Stage
Superficial (n=111) 22 (19.8) 20 (18.0) 47 (42.3) 18 (16.2) 4 (3.6) <0.001
Invasive (n=63) 38 (60.3) 19 (30.2) 4 (6.3) 1 (1.6) 1 (1.6)
Grade
Low (n=116) 24 (20.7) 24 (20.7) 46 (39.7) 18 (15.5) 4 (3.4) <0.001
High (n=58) 36 (62.1) 15 (25.9) 5 (8.6) 1 (1.7) 1 (1.7)
Superficial recurrence
No recurrence (n=72) 18 (25.0) 15 (20.8) 30 (41.7) 8 (11.1) 1 (1.4) <0.003
Recurrence (n=39) 4 (10.3) 5 (12.8) 17 (43.6) 10 (25.6) 3 (7.7)
Progression
No progression (n=135) 40 (29.6) 24 (17.8) 50 (37.0) 17 (12.6) 4 (3.0) <0.001
Progression (n=39) 20 (51.3) 15 (38.5) 1 (2.6) 2 (5.1) 1 (2.6)
Survival
Alive (n=137) 39 (28.5) 26 (19.0) 50 (36.5) 17 (12.4) 5 (3.6) <0.001
Dead (n=37) 21 (56.8) 13 (35.1) 1 (2.7) 2 (5.4) 0 (0)
Table 3. Clinico-pathological features and FOXO1 immunohistochemical staining scores of primary bladder transitional cell carcinomasRelationship Between Bladder Cancer and Expression of FOXO1 and FOXG1 473
al level.
Our data demonstrate that FOXO1 expression is enhanced
in superficial bladder cancer compared to invasive cancer and
that FOXO1 expression levels are higher in low-grade cancers
(grades 1 and 2) compared to high-grade cancers (grade 3).
Bladder cancers with increased FOXO1 expression exhibited
pathological features of less aggressive, superficial and low-
grade bladder cancers. There is a clear survival advantage for
the advanced cancer cell that can protect itself from apopto-
sis. However, a rapidly growing, infiltrative, advanced tumor
that is outgrowing its blood supply and mutating its DNA
may have enhanced activation of an apoptosis-related path-
way despite protective mechanisms acquired by the tumor
cells. However, it remains unclear why FOXO1 expression
increases in superficial cancers as compared to invasive tumors.
Although the immunohistochemical findings were not st-
atistically significant, the expression levels of FOXO1 mRNA
in primary superficial bladder cancer tissues were significant-
ly higher in non-recurred than in recurred patients in our
study. When comparing primary bladder cancer cases that
had progressed with those that had not, we observed signif-
icantly higher expression of FOXO1 in the latter group and
higher levels of FOXG1 in the former. We observed a nega-
tive correlation between the levels of FOXO1 and FOXG1
mRNA expression in bladder cancer tissue, a finding support-
ed by Aoki et al., who demonstrated that FOXG1 strongly
inhibited FOXO1-mediated transcriptional activation (17).
These results indicate that FOXO1 and FOXG1 expression
may be useful prognostic markers for bladder cancer progres-
sion. Patients with enhanced FOXO1 expression exhibited a
higher disease-free survival rate than those with low FOXO1
expression, implying that enhanced FOXO1 expression might
suppress disease progression and provide a survival benefit for
bladder cancer patients. These findings are further supported
by the multivariate analysis, which showed that the cancer
stage and FOXO1 mRNA expression level were strong pre-
dictors of cancer progression and disease-free survival.
In conclusion, enhanced expression of FOXO1 and FOXG1
are strongly associated with bladder cancer development.
Moreover, enhanced expression of FOXO1 is positively asso-
ciated with low rate of recurrence or progression and with
survival, whereas increased expression of FOXG1 correlates
to disease progression. Thus these genes may be useful prog-
nostic markers for human bladder cancers.
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